Capricor Therapeutics, Inc. (CAPR)

NASDAQ: CAPR · Real-Time Price · USD
11.12
+0.11 (1.00%)
At close: May 21, 2025, 4:00 PM
11.16
+0.04 (0.36%)
After-hours: May 21, 2025, 7:50 PM EDT
1.00%
Market Cap 508.27M
Revenue (ttm) 17.36M
Net Income (ttm) -55.06M
Shares Out 45.71M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE 41.57
Dividend n/a
Ex-Dividend Date n/a
Volume 3,176,740
Open 10.83
Previous Close 11.01
Day's Range 10.72 - 11.71
52-Week Range 3.52 - 23.40
Beta 0.86
Analysts Strong Buy
Price Target 41.67 (+274.73%)
Earnings Date May 13, 2025

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 160
Stock Exchange NASDAQ
Ticker Symbol CAPR
Full Company Profile

Financial Performance

In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $41.67, which is an increase of 274.73% from the latest price.

Price Target
$41.67
(274.73% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

14 hours ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

1 day ago - Accesswire

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...

1 day ago - Seeking Alpha

CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Capricor Therapeutics...

1 day ago - PRNewsWire

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com...

2 days ago - Accesswire

Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer ...

8 days ago - Seeking Alpha

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas...

15 days ago - GlobeNewsWire

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related...

16 days ago - Reuters

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date-   SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) --   Capr...

16 days ago - GlobeNewsWire

Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Office...

2 months ago - Seeking Alpha

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...

2 months ago - GlobeNewsWire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--

2 months ago - GlobeNewsWire

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

PARAMUS, N.J. , March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd.

2 months ago - PRNewsWire

Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...

2 months ago - GlobeNewsWire

Capricor: Further Value Unlocked With Priority Review Of Deramiocel

Capricor Therapeutics, Inc.'s Deramiocel received FDA Priority Review with a PDUFA target date of August 31, 2025, for the treatment of patients with DMD Cardiomyopathy. Deramiocel could become the fi...

2 months ago - Seeking Alpha

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

On Tuesday, the FDA accepted for review Capricor Therapeutics Inc's CAPR Biologics License Application for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duche...

2 months ago - Benzinga

Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrate...

3 months ago - Seeking Alpha

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DI...

4 months ago - GlobeNewsWire

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...

Other symbols: MESOXBI
5 months ago - Market Watch

Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significan...

5 months ago - Seeking Alpha

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented pr...

5 months ago - Seeking Alpha

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...

6 months ago - GlobeNewsWire

Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Off...

6 months ago - Seeking Alpha

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...

6 months ago - GlobeNewsWire

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...

7 months ago - GlobeNewsWire